Brooklyn Investment Group Invests $173,000 in Becton, Dickinson and Company (NYSE:BDX)

Brooklyn Investment Group bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 718 shares of the medical instruments supplier’s stock, valued at approximately $173,000.

Other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. PineStone Asset Management Inc. raised its stake in Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after buying an additional 788,735 shares in the last quarter. First Eagle Investment Management LLC lifted its holdings in Becton, Dickinson and Company by 32.5% during the 2nd quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after buying an additional 688,296 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its position in shares of Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock worth $1,293,635,000 after acquiring an additional 460,440 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $108,243,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of several recent analyst reports. Evercore ISI boosted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Down 1.0 %

BDX opened at $221.96 on Thursday. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89. The business has a 50 day moving average price of $234.64 and a two-hundred day moving average price of $234.32. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The company has a market cap of $64.16 billion, a PE ratio of 37.37, a P/E/G ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the prior year, the business earned $3.42 earnings per share. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.87%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s payout ratio is 63.97%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.